Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to UCL and Ludwig Institute.

iTeos Therapeutics, a US-based immuno-oncology drug spinout of Université catholique de Louvain (UCL) and Ludwig Institute for Cancer Research, raised more than $201m in a listing on Friday.
The company priced its shares at $19, above its previous target of $18, and upped the number of shares by approximately 350,000 to 10.58 million. It has listed on the Nasdaq Global Market using the ticker symbol ITOS.
Founded in 2011, iTeos is developing immunotherapies aimed at a wide range…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in